Monitor for the actual Form 4 filing to confirm the sale was executed. The small size and routine nature of this insider sale suggest no material read-through for the stock.
Price Chart
Executive Summary
Andrew J. Murphy, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 4,147 shares of common stock, with an approximate market value of $3.2 million based on the filing date. The shares were acquired through the exercise of stock options on October 13, 2026, and the sale is planned for October 14, 2026. This is a routine insider sale following option exercise, representing a small fraction of the company's market cap and is not indicative of a change in business outlook.
Key Facts
- Insider Andrew J. Murphy (Officer) filed Form 144 to sell 4,147 shares of Regeneron common stock.
- Estimated sale value is approximately $3.2 million based on the filing date.
- Shares were acquired via exercise of stock options on October 13, 2026.
- The sale is planned for execution on October 14, 2026.
- The filing is a notice of intent to sell, not a completed transaction.
Financial Impact
Approximately $3.2 million in shares to be sold, a small amount relative to Regeneron's multi-billion dollar market cap.
Risk Factors
- Insider sale may signal personal liquidity needs rather than a bearish view on the company.
- Form 144 is only an intent to sell; the transaction may not occur.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001073 |
| Document: 0001969223-26-001073-index.html | 0001969223-26-001073 |
| Document: 0001969223-26-001073.txt | 0001969223-26-001073 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 2d ago | Press Release | $807.67 | awaiting T+5 | awaiting T+5 | $813.27 (+0.69%) |
Oct 25, 2026 3d ago | Press Release | $807.67 | awaiting T+5 | awaiting T+5 | $813.27 (+0.69%) |
Oct 23, 2026 5d ago | Institutional Cluster | $805.02 | awaiting T+5 | awaiting T+5 | $813.27 (−1.02%) |
Oct 15, 2026 13d ago | ANALYST-UPGRADE | $790.74 $805.02 | ▲ +1.81% | ▲ +2.24% | $813.27 (+2.85%) |
Oct 14, 2026 14d ago | 144 | $796.34 $819.09 | ▲ +2.86% | ▲ +3.87% | $813.27 (+2.13%) |
Oct 6, 2026 22d ago | 8-K | $738.72 $753.12 | ▲ +1.95% | ▲ +2.09% | $813.27 (+10.09%) |
Oct 1, 2026 27d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $813.27 (+10.68%) |
Oct 1, 2026 27d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $813.27 (+10.68%) |
Oct 1, 2026 27d ago | ANALYST-UPGRADE | No price | awaiting T+5 | awaiting T+5 | No price |
Oct 1, 2026 28d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $813.27 (+10.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers